Hikal Ltd. Share Price & Stock Analysis

Hikal Ltd. (BSE: 524735) is a Navi Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹2,758 Cr, it ranks #1,090 by market cap among the 6,197 Indian listed companies on FinBizNet, and #34 of 86 in Medicinal Chemicals and Botanical Products. At ₹223.65 (as of 16 Nov 2026), the share price is 14.3% below its 52-week high of ₹261.00 and 52.9% above its 52-week low of ₹146.25. The share price is down 5.6% over one year and up 2.8% over three months.

Key Metrics

Current Price₹223.65
Market Cap₹2,758 Cr
BSE Code524735
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E RatioNot meaningful (loss)
Return on Equity-3.97%
Return on Assets1.45%
52-Week Range₹146.25 – ₹261.00
1-Year Price Change-5.6%
3-Month Price Change+2.8%
Beta (1Y)0.88
Dividend Yield0.36%
HeadquartersNavi Mumbai, Maharashtra
Websitewww.hikal.com

Latest Quarterly Results — Q2 FY27

Revenue₹434 Cr
Net Profit₹-6 Cr
Net Margin-1.4%
EPS (Basic)₹-0.49
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Hikal Ltd. Quarterly Revenue and Profit Trend

Hikal Ltd. reported revenue of ₹434 Cr in Q2 FY27, up 36.3% from ₹319 Cr in Q2 FY26 and up 7.8% from ₹403 Cr in Q1 FY27. It posted a net loss of ₹6 Cr for the quarter, against a net loss of ₹35 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹319 Cr (Q2 FY26) to ₹552 Cr (Q4 FY25). The company reported a net loss in 5 of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹434 Cr−₹6 Cr−1.4%
Q1 FY27₹403 Cr−₹7 Cr−1.8%
Q4 FY26₹519 Cr₹14 Cr2.8%
Q3 FY26₹494 Cr−₹6 Cr−1.2%
Q2 FY26₹319 Cr−₹35 Cr−11.0%
Q1 FY26₹380 Cr−₹22 Cr−5.9%
Q4 FY25₹552 Cr₹50 Cr9.1%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 68.85% of Hikal Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 37.8% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Hikal Ltd.

Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as

Products and Services

1. Crop Protection Products-This segment manufactures pesticides and herbicides. It is also involved in custom synthesis and custom manufacturing of intermediates and active ingredients. 2. Pharmaceuticals-This segment produces in active pharmaceutical ingredients. It is also involved in contract research activities. 3. Corporate / Unallocated Segment-0 4. Pharmaceuticals - Overseas Operation-This segment manufactures and supplies active pharmaceutical ingredients in India. It also engages in the contract research, custom synthesis, and custom manufacture of active pharmaceutical ingredients.

Business Segments

1. Pharmaceuticals-59.6% 2. Crop Protection-40.4%

Hikal Ltd. vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Hikal Ltd.₹2,758 Crn/m-3.97%₹434 Cr-5.6%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Hikal Ltd.?

Hikal Ltd. is trading at ₹223.65, with a market capitalisation of ₹2,758 Cr.

Which sector does Hikal Ltd. belong to?

Hikal Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Hikal Ltd.?

Hikal Ltd. has a return on equity of -3.97%.

What is the stock symbol of Hikal Ltd.?

Hikal Ltd. is listed on the BSE under the scrip code 524735.

How has Hikal Ltd.'s share price moved over the past year?

Hikal Ltd.'s share price is down 5.6% over one year and up 2.8% over three months. Its 52-week range is ₹146.25 to ₹261.00.

What were Hikal Ltd.'s latest quarterly results?

In Q2 FY27, Hikal Ltd. reported revenue of ₹434 Cr and net profit of ₹-6 Cr, with basic EPS of ₹-0.49 (consolidated, parsed from the company's exchange filing).

How have Hikal Ltd.'s revenue and profit changed over the past year?

Hikal Ltd. reported revenue of ₹434 Cr in Q2 FY27, up 36.3% from ₹319 Cr in Q2 FY26 and up 7.8% from ₹403 Cr in Q1 FY27.

What is the promoter holding in Hikal Ltd.?

Promoters held 68.85% of Hikal Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.